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Abstract
 Background & Aims—Functional status (a patient’s ability to perform activities that meet 
basic needs, fulfill usual roles, and maintain health and well being) has been linked to outcomes in 
patients with cirrhosis and can be measured by the Karnofsky performance status (KPS) scale. We 
investigated the association between KPS score and mortality in patients with cirrhosis.
 Methods—We used the United Network for Organ Sharing database to perform a retrospective 
cohort study of patients listed for liver transplantation in the United States between 2005 and 
2015. We used Cox proportional hazards and competing risk regression analyses to examine the 
association between KPS and mortality and transplantation.
 Results—Of 79,092 patients, 44% were in KPS category A (KPS 80%–100%), 43% were in 
category B (KPS 50%–70%), and 13% were in category C (KPS 10%–40%). Between 2005 and 
2015, the proportion of patients in category A decreased from 53% to 35%, whereas the 
proportions in categories B and C increased from 36% to 49% and from 11% to 16%, respectively. 
KPS was associated with mortality: compared to patients in KPS category A, the KPS B adjusted 
hazard ratio [HR] was 1.14 (95% confidence interval [CI], 1.11–1.18) and the KPS C adjusted HR 
was 1.63 (95% CI, 1.55–1.72). KPS was also associated with liver transplantation; compared to 
patients in KPS category A, the KPS B adjusted HR was 1.08 (95% CI, 1.06–1.11) and the KPS C 
adjusted HR was 1.35 (95% CI, 1.30–1.40). In competing risk analysis, only the relationship 
between KPS and mortality maintained significance and directionality. These relationships were 
most pronounced in patients without hepatocellular carcinoma.
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 Conclusions—Among patients with cirrhosis listed for liver transplantation, poor 
performance status, based on the KPS scale, is associated with increased mortality. In this 
population, performance status has decreased over time.
Keywords
survival; death; liver disease; UNOS; waitlist
 INTRODUCTION
Cirrhosis is a highly morbid condition characterized by complications including ascites, 
hepatic encephalopathy, malnutrition, and sarcopenia. These complications can impair 
quality of life, mental health, and physical function. Functional status refers to an 
individual’s ability to perform activities that meet basic needs, fulfill usual roles, and 
maintain health and well-being.1 Functional status is diminished in patients with cirrhosis, 
and for these patients, measures of functional status have prognostic value. Frailty, a closely-
related concept indicating impaired physiologic reserve, is associated with mortality, length 
of stay, and rehabilitation needs in hospitalized patients with cirrhosis.2 Frailty and 
decreased 6-minute walking distance are associated with death and diminished quality of life 
in liver transplant candidates.3–5
Functional status can be measured by the Karnofsky performance status (KPS), a simple, 11-
point scale expressed as a percentage of physical function ranging from 100% (normal, no 
complaints, no evidence of disease) to 0% (dead).6 It is widely used in oncology to help 
guide treatment and clinical trials.7–10 It has good interrater reliability and construct 
validity.11, 12 It predicts outcomes in multiple populations, including chronic kidney 
disease,13 heart failure,14 and HIV.15 For patients with liver disease, the closely related 
Eastern Cooperative Oncology Group (ECOG) performance status is associated with 
mortality after liver transplant and in patients with hepatocellular carcinoma (HCC).16, 17 
Notably, performance status is included in the Barcelona Clinic Liver Cancer staging 
system.18 Despite its widespread use, the KPS scale has not been examined in patients with 
cirrhosis.
We aimed to examine the association between KPS and mortality in waitlisted patients with 
cirrhosis. Our hypothesis was that patients with worse performance status would have 
greater mortality after adjusting for other measures of disease severity. To address this 
question, we examined the United Network for Organ Sharing (UNOS) database, which 
contains information on all patients listed for liver transplantation in the US. Compared to 
prior studies of frailty, which were all single-center,2–5 the UNOS database offers the 
advantages of (1) a large population-wide analysis from multiple centers and (2) the use of 
KPS data collected as part of routine clinical care, allowing for improved generalizability.
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 METHODS
 Study Sample
For this retrospective cohort study, we obtained standard transplant analysis and research 
files from UNOS, which contains data through September 25, 2015 on all patients listed for 
solid organ transplant in the US. We limited the study to adults ≥ 18 years of age listed for 
liver transplant on or after April 1, 2005. Prior to that date, KPS was not routinely recorded.
Of the 110,359 adults, we excluded subjects with previous liver transplant (n = 3,759), 
multiple simultaneous organ transplant listings (n = 9,831), a non-cirrhosis diagnosis (n = 
2,271), and acute liver failure (n = 4,553). Patients who transferred to another center or 
received a transplant at another center were excluded to avoid double-counting patients with 
multiple listings (n = 4,226). Similar to previous studies,19 patients with fewer than 5 days 
of waitlist time were also excluded (n = 8,368), as functional status may not be meaningful 
in this short time period. Finally, we excluded those missing KPS (n = 4,165) and those with 
extreme laboratory values suggesting data entry error: body mass index (BMI) < 15 or > 50 
kg/m2, serum albumin > 6 g/dL, and serum sodium > 170 meq/L (n = 667). The study was 
approved by the Indiana University Institutional Review Board.
 Outcomes
The primary outcome was removal from the waitlist due to death, clinical deterioration, or 
medical unsuitability (combined into a single mortality outcome). We also examined liver 
transplant as a secondary outcome. Patients removed from the waitlist for improved 
condition, loss to follow-up, removal in error, transplant refusal, and “other” were censored 
in survival analyses.
 Karnofsky Performance Status
Since April 2005, transplant centers have captured functional status using the KPS scale, 
which is expressed in 10% increments.6 We further classified KPS into three categories 
according to the patient’s ability to work or provide self-care as previously described.6, 9 
Patients with KPS category A are able to carry on normal activity and work; patients with 
KPS B are unable to work, but are able to live at home and care for personal needs; and 
patients with KPS C are unable to provide self-care (Supplementary Table).
 Variables
We considered additional variables collected at listing that could influence outcomes. These 
included age; sex; race/ethnicity (white, black, Hispanic, and other); BMI; diabetes; dialysis; 
model for end-stage liver disease (MELD) score; serum albumin and sodium; presence of 
ascites (absent, slight, and moderate) and hepatic encephalopathy (none, grade 1–2, grade 3–
4); ABO blood group; transplant region; listing year; and underlying liver disease. The 
underlying disease was categorized as alcohol, hepatitis C, alcohol/hepatitis C, nonalcoholic 
steatohepatitis, hepatitis B, cryptogenic cirrhosis, autoimmune hepatitis, primary biliary 
cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma, and other. Patients with 
HCC and another diagnosis (e.g. hepatitis C) were categorized as HCC because of 
differences in organ allocation.20
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 Statistical Analysis
Patients were followed from listing to removal from the waitlist for any reason. Those who 
were still on the waitlist on September 25, 2015, were censored. Categorical variables were 
reported as proportions and counts. Continuous variables were reported as either means and 
standard deviations (SD) or medians and ranges. Bivariate comparisons were performed with 
Pearson’s χ2 test, one-way analysis of variance, or the Kruskal-Wallis test. We used Cox 
proportional hazards regression to determine the association between KPS and either death 
or transplantation, with and without adjustment for covariates. The proportional hazards 
assumption was verified using log-log plots and Schoenfeld residuals. We repeated the 
models using an alternative outcome, grouping waitlist removals for “other” reasons as due 
to death or clinical deterioration because many patients removed for “other” reasons actually 
have deterioration.21 Additionally, we repeated the models including those missing KPS and 
assigning them to either KPS A or KPS C. We also performed subgroup analyses in patients 
with and without HCC, given the differences in organ allocation.20 Interaction terms were 
added to the models to confirm subgroup differences. In addition to considering cause-
specific hazards using the Cox models, we used competing risk regression to estimate 
differences in the cumulative incidence of mortality and transplantation.22 These models 
account for competing outcomes that prevent the outcome of interest. For instance, death 
prevents future liver transplantation, and liver transplantation prevents pre-transplant death. 
In contrast, Cox proportional hazards models assume that outcomes may still occur after 
censoring. We also estimated the cumulative incidence of death and transplantation while 
accounting for the competing risks as previously described.23 All p-values were based on 2-
sided tests and were considered statistically significant when p < 0.05. Analyses were 
performed using Stata version 13 (StataCorp LP, College Station, TX).
 RESULTS
79,092 patients listed for transplant met the inclusion and exclusion criteria. The mean KPS 
was 68.6% (SD 20.1). 34,775 patients (44.0%) were category A (KPS 80 – 100%), 33,705 
(42.6%) were category B (KPS 50 – 70%), and 10,612 (13.4%) were category C (KPS 10 – 
40%). The groups were similar with regards to the prevalence of diabetes, BMI, and serum 
albumin and sodium (Table 1). Differences in these variables were statistically significant as 
a result of the large sample size. Group C was younger, had more women, and more 
Hispanic patients. Group C also had higher illness severity, with more patients on dialysis, 
greater mean MELD score, and more patients with ascites and hepatic encephalopathy. 
Group C also had more patients with alcoholic liver disease and fewer with HCC. For the 
17,138 patients with HCC, the mean KPS was 80% (SD 15.6); 55.3% were KPS A, 39.7% 
were KPS B, and 5.0% were KPS C. There was significant regional variation in KPS: the 
mean KPS ranged from 64% to 75%. The ABO blood groups were similar in the KPS 
categories. Between 2005 and 2015, the proportion of patients in category A decreased from 
53.3 to 35.1% (34% decrease), while the proportion in categories B and C increased from 
35.7 to 49.3% (38% increase) and from 11.0 to 15.6% (42% increase), respectively (Figure 
1).
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During a median follow-up of 0.54 years (interquartile range 0.16–1.52 years), 40,344 
patients (51.0%) received a transplant, 17,999 (22.8%) were removed from the waitlist for 
death or deterioration, 5,840 (7.4%) were removed for “other” reasons, and 14,909 (18.9%) 
were still alive at last follow-up. 5-year cumulative incidence curves show an increase in 
both mortality and transplant with declining KPS (Figure 2). The 1-year incidence of death 
is 11.4% for KPS A, 15.5% for KPS B, and 27.4% for KPS C, and the 1-year incidence of 
transplant is 38.7%, 44.7%, and 53.4%.
In the Cox models, worse KPS was associated with increased risk for death/deterioration 
and/or transplantation (Table 2). These differences persisted after adjustment for multiple 
variables. As compared to KPS A, the adjusted hazard ratio (HR) for death/deterioration for 
KPS B was 1.14 (95% confidence interval [CI], 1.11 – 1.18) and for KPS C was 1.63 (95% 
CI, 1.55 – 1.72). The association between KPS and transplant appeared less pronounced: 
KPS B adjusted HR 1.08 (95% CI, 1.06 – 1.11), and KPS C adjusted HR 1.35 (95% CI, 1.30 
– 1.40). These relationships were confirmed in analyses where patients removed from the 
waitlist for “other” reasons were reclassified as death/deterioration and where patients with 
missing KPS were included and assigned to KPS A and C (data not shown).
In competing risk regression, where death and transplantation are considered competing 
outcomes rather than being censored, the association between KPS and death/deterioration 
was confirmed (Table 2). This association was also present in the adjusted model: KPS B 
adjusted subhazard ratio (SHR) 1.08 (95% CI, 1.04 – 1.11), and KPS C adjusted SHR 1.26 
(95% CI, 1.20 – 1.33). KPS was also associated with transplantation in the univariate model, 
but in the adjusted model, the association was markedly attenuated and without 
directionality (SHR 1.06 for both KPS B and C).
The addition of interaction terms to the Cox models for mortality and transplantation 
confirmed significant differences in those with and without HCC. Results of the 
multivariable Cox models in those with and without HCC are shown in Figure 3. For those 
without HCC, worsening KPS was associated with increased mortality and transplantation. 
These relationships also held for patients with HCC, although the associations were 
attenuated, and, for KPS B, the associations with transplantation and combined death or 
transplantation lost statistical significance. Associations with mortality were similar when 
patients with “other” removals were reclassified as having died and when patients with 
missing KPS were included and assigned to KPS A and C (data not shown).
In competing risk models, for those without HCC, there remained an increase in the risk of 
death with worsening KPS: KPS B adjusted SHR 1.07 (95% CI, 1.03 – 1.10) and KPS C 
adjusted SHR 1.28 (95% CI, 1.21 – 1.35) (Figure 4). This relationship was also seen in the 
univariate model for the HCC subgroup (KPS B unadjusted SHR 1.30; 95% CI, 1.18 – 1.42; 
KPS C SHR 1.74; 95% CI, 1.45 – 2.08), but not after adjustment (Figure 4). In those without 
HCC, worsening KPS was also associated with greater likelihood of transplantation in 
univariate analysis (KPS B unadjusted SHR 1.33; 95% CI, 1.29 – 1.36; KPS C SHR 2.00; 
95% CI, 1.92 – 2.07). However, after adjustment, KPS did not have a consistent association 
with transplant.
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 DISCUSSION
Patients with cirrhosis suffer from physical debility that can interfere with activities and 
impair quality of life. In this study of patients listed for transplant, worse functional status as 
measured by KPS was associated with increased mortality. KPS was also associated with 
greater propensity to receive a liver transplant, though this relationship did not hold after 
considering death as a competing outcome.
These findings add to the literature linking functional status to outcomes for patients with 
cirrhosis. Carey et al. showed that 6-minute walking distance predicts waitlist mortality.4 Lai 
and colleagues also demonstrated increased waitlist mortality with increasing frailty, 
measured by performance-based testing and patient self-report.3 In hospitalized patients with 
cirrhosis, frailty assessments were associated with 90 day mortality.2 Beyond confirming the 
relationship between functional status and mortality, this study provides novel additions. 
Compared to previous single-center studies, this study reflects outcomes across US 
transplant centers. The large sample size also allows adjustment for more confounders than 
could be achieved previously. Finally, the UNOS database can be used to examine trends in 
functional status amongst all patients on the national waitlist. The KPS scale, which has not 
been previously examined in this context, is widely used clinically and is ubiquitous in 
oncology.9 It is simple and can be performed by any provider, with good reliability and 
validity.11, 12 It is also already recorded widely for patients with cirrhosis at the time of 
transplant listing.
An important addition is the comparison of mortality and transplant. These related outcomes 
have a complex relationship, and can be modeled using both Cox regression, which treats 
outcomes independently, and competing risks regression, which considers outcomes 
together. Both methods are valuable and provide complementary insight.24 When considered 
independently, both mortality and transplant are more likely with declining KPS. However, 
when considered together, those with worse KPS do not appear more likely to receive a 
transplant, since the SHR approaches one and loses directionality. Reasons for this 
relationship are likely complex, and may include a balance between (1) the desire to 
transplant those with poor performance status who are most in need and (2) a reluctance to 
transplant sicker patients due to worse potential post-transplant outcomes.16 Although the 
relationship between KPS and death is also attenuated when considering competing 
outcomes, the directionality is maintained. Therefore, KPS may have a stronger influence on 
mortality as compared to transplant.
Differences in these relationships in patients with and without HCC are also important. In 
Cox models, the relationships between KPS and both outcomes were maintained, although 
attenuated for the HCC group. In competing risks models, the only relationship that 
maintained significance and directionality was for mortality in those without HCC. This 
suggests that KPS may be more important in patients without HCC. This finding may relate 
to the selection of patients with HCC for transplant. These patients have lower native MELD 
scores, higher transplant rates, and lower mortality as compared to non-HCC patients.20 We 
found that the HCC group had higher KPS, consistent with guidelines favoring transplant for 
HCC patients with better performance status.18
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Two important findings related to KPS in the waitlist population deserve mention. First, the 
proportion with KPS B and C is increasing, with a concomitant decrease in KPS A. These 
changes mirror trends in the broader population, which is aging,25 accumulating 
comorbidities,26,27 and requiring more help with activities of daily living.28 Taken with the 
increased waitlist mortality for those with worse KPS, this trend is cause for concern. 
Similar projected changes in the organ donor population could also lead to declining 
numbers of liver transplants, further impacting waitlist mortality.29 Finally, patients with 
worse KPS may be less likely to be considered for transplant by risk-averse programs given 
the negative impact on post-transplant outcomes.16 Together, these trends could result in 
fewer transplants and increased waitlist mortality in the future. In this context, interventions 
to improve functional status may have an important role for patients with cirrhosis. Another 
important finding is the KPS regional variation. This variation may reflect known regional 
differences in disease severity, accompanied by differences in mortality and transplant 
rates.20 Alternatively, both regional variation and temporal trends in KPS may simply reflect 
differences in KPS assessment. In particular, the temporal trend might reflect improved 
assessment by transplant physicians as they accumulate experience with KPS.
Although this study provides novel information, it does have several limitations. First, the 
study only includes patients listed for transplant in the US. Additional studies of patients in 
other populations are needed to generalize the findings. KPS is recorded by individual 
transplant centers at listing, and many providers nationwide contribute to these KPS 
assessment. KPS has excellent interrater reliability in cancer populations;11, 12 however, in 
other populations its test characteristics are less well-established, and it has not been 
previously tested in cirrhosis. The closely related ECOG performance status has been 
studied in cirrhosis, and is associated with post-transplant mortality and HCC mortality.16, 17 
However, in these studies reliability was not specifically measured. In our study, suboptimal 
reliability could account for regional variation and temporal trends in KPS. However, the 
potential for interrater variability is limited to a degree by the KPS categorization. Only 
ratings that differ across categories would impact the findings (e.g. KPS 40% vs. 50%), 
while variations within categories would have no impact (e.g. 50% vs. 60%). Nevertheless, 
further study of KPS validity and reliability are needed to support its use in the cirrhosis 
population. Finally, although KPS appears to influence mortality more than transplant, the 
absolute cumulative incidence of transplant is greater than death for all KPS categories. 
Therefore, prognosis cannot be assessed on the basis of KPS alone. Despite these 
limitations, this study benefits from a large sample size, which provides a comprehensive 
picture of patients listed for transplantation in the US. The large sample size also allows for 
analyses adjusting for multiple important confounders.
In conclusion, KPS is associated with mortality in patients with cirrhosis listed for liver 
transplantation. We also found that KPS amongst patients listed for transplant in the US has 
been worsening over the last decade. These novel findings underscore the importance of 
physical functioning in patients with cirrhosis and its potential growing impact on outcomes 
in this population. Future studies are needed to assess interventions to improve functional 
status and improve outcomes.
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Figure 1. 
Temporal changes in Karnofsky performance status of patients listed for liver transplantation 
in the United States.
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Figure 2. 
Five-year cumulative incidences of death/deterioration and liver transplantation according to 
Karnofsky performance status.
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Figure 3. 
Relationship between Karnofsky performance status and clinical outcomes in patients with 
and without hepatocellular carcinoma. Estimates and confidence intervals are based on the 
multivariable Cox proportional hazards models.
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Figure 4. 
Relationship between Karnofsky performance status and clinical outcomes in patients with 
and without hepatocellular carcinoma. Estimates and confidence intervals are based on the 
multivariable competing risk models.
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Table 1
Baseline Characteristics According to Karnofsky Performance Status
Characteristic Karnofsky A
n = 34,775
Karnofsky B
n = 33,705
Karnofsky C
n = 10,612
p-value
Age, years, mean (SD) 55.0 (9.6) 55.3 (9.0) 53.7 (10.1) < 0.001
% Male 68.7 64.8 62.1 < 0.001
Race/ethnicity < 0.001
 % White 71.8 72.5 68.0
 % Black 8.4 7.2 8.3
 % Hispanic 13.4 15.4 18.1
 % Other 6.4 4.8 5.6
BMI, kg/m2, mean (SD) 28.6 (5.4) 28.8 (5.6) 28.7 (6.1) < 0.001
% Diabetes 24.9 27.3 25.3 < 0.001
% Dialysis 0.3 0.6 10.1 < 0.001
MELD score, mean (SD) 13.3 (5.3) 15.6 (6.3) 24.6 (9.7) < 0.001
Serum albumin, g/dL, mean (SD) 3.2 (0.7) 3.0 (0.6) 3.0 (0.7) < 0.001
Serum sodium, meq/L, mean (SD) 136.9 (4.1) 135.7 (4.7) 135.1 (6.0) < 0.001
Ascites < 0.001
 % Absent 38.1 23.3 15.5
 % Slight 51.3 55.6 42.3
 % Moderate 10.6 21.1 42.3
Hepatic encephalopathy < 0.001
 % None 54.6 35.1 25.3
 % Grade 1–2 43.8 60.5 59.4
 % Grade 3–4 1.6 4.4 15.3
Liver disease < 0.001
 Alcohol 12.8 17.1 22.7
 Hepatitis C 23.6 24.8 24.7
 Alcohol/Hepatitis C 4.4 6.3 6.5
 Nonalcoholic steatohepatitis 7.0 9.5 9.1
 Cryptogenic 5.1 5.9 6.5
 Hepatocellular carcinoma 27.2 20.2 8.0
 Hepatitis B 1.7 1.4 2.8
 Primary sclerosing cholangitis 5.6 3.3 2.9
 Primary biliary cirrhosis 3.0 2.9 2.9
 Autoimmune hepatitis 2.8 2.6 3.9
 Other 6.7 6.0 10.1
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Table 2
Relationship Between Karnofsky Performance Status and Clinical Outcomes
Unadjusted Hazard Ratioa Adjusted Hazard Ratiob Unadjusted Subhazard Ratioa Adjusted Subhazard Ratiob
Death/deterioration
 Karnofsky A 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
 Karnofsky B 1.42 (1.37–1.47) 1.14 (1.11–1.18) 1.17 (1.14–1.21) 1.08 (1.04–1.11)
 Karnofsky C 3.65 (3.50–3.81) 1.63 (1.55–1.72) 1.80 (1.72–1.88) 1.26 (1.20–1.33)
Transplantation
 Karnofsky A 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
 Karnofsky B 1.24 (1.22–1.27) 1.08 (1.06–1.11) 1.15 (1.12–1.17) 1.06 (1.03–1.08)
 Karnofsky C 2.41 (2.34–2.48) 1.35 (1.30–1.40) 1.54 (1.49–1.59) 1.06 (1.02–1.11)
Death or Transplantation
 Karnofsky A 1 (Ref) 1 (Ref) N/A N/A
 Karnofsky B 1.29 (1.27–1.32) 1.10 (1.08–1.12)
 Karnofsky C 2.74 (2.68–2.81) 1.44 (1.40–1.48)
a
Hazard ratios are derived from Cox proportional hazards models; subhazard ratios are derived from competing risks regression models.
bAdjusted for age, sex, race, diabetes, dialysis, BMI, blood group, MELD score, serum albumin, sodium, ascites, encephalopathy, underlying liver 
disease, transplant region, and year of listing.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 August 01.
